Eli Lilly’s $1 trillion market cap may overtake SpaceX’s expected $1.8 trillion IPO valuation amid historical IPO underperformance trends.
An analyst predicts Eli Lilly will exceed SpaceX’s valuation within two years, despite SpaceX’s anticipated $1.8 trillion IPO, one of the largest in history. Eli Lilly currently holds a $1 trillion market cap, driven by its leadership in obesity drug development.
Historical data suggests IPOs often underperform broader markets post-listing. A study by Dimensional Fund Advisors found IPO stocks lagged market benchmarks over 18-year periods, with companies typically going public during peak hype to maximize capital.
SpaceX’s IPO, though highly anticipated, may face similar challenges, while Eli Lilly’s established pharmaceutical dominance could sustain growth.